Current potential pathogenic mechanisms of copper-zinc superoxide dismutase 1 (SOD1) in amyotrophic lateral sclerosis
Author:
Wang Xin-Xin12, Chen Wen-Zhi1, Li Cheng1, Xu Ren-Shi12ORCID
Affiliation:
1. Department of Neurology, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, The Clinical College of Nanchang Medical College, National Regional Center for Neurological Diseases , Xiangya Hospital of Central South University, Jiangxi Hospital , Nanchang 330006 , Jiangxi Province , China 2. Medical College of Nanchang University , Nanchang 330006 , Jiangxi Province , China
Abstract
Abstract
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease which damages upper and lower motor neurons (UMN and LMN) innervating the muscles of the trunk, extremities, head, neck and face in cerebrum, brain stem and spinal cord, which results in the progressive weakness, atrophy and fasciculation of muscle innervated by the related UMN and LMN, accompanying with the pathological signs leaded by the cortical spinal lateral tract lesion. The pathogenesis about ALS is not fully understood, and no specific drugs are available to cure and prevent the progression of this disease at present. In this review, we reviewed the structure and associated functions of copper-zinc superoxide dismutase 1 (SOD1), discuss why SOD1 is crucial to the pathogenesis of ALS, and outline the pathogenic mechanisms of SOD1 in ALS that have been identified at recent years, including glutamate-related excitotoxicity, mitochondrial dysfunction, endoplasmic reticulum stress, oxidative stress, axonal transport disruption, prion-like propagation, and the non-cytologic toxicity of glial cells. This review will help us to deeply understand the current progression in this field of SOD1 pathogenic mechanisms in ALS.
Funder
Education Department of Jiangxi Province Jiangxi Provincial Department of Science and Technology Health and Family Planning Commission of Jiangxi Province National Natural Science Foundation of China
Publisher
Walter de Gruyter GmbH
Reference131 articles.
1. Alqallaf, A., Cates, D.W., Render, K.P., and Patel, K.A. (2024). Sodium phenylbutyrate and taurursodiol: a new therapeutic option for the treatment of amyotrophic lateral sclerosis. Ann. Pharmacother. 58: 165–173, https://doi.org/10.1177/10600280231172802. 2. Arredondo, C., Cefaliello, C., Dyrda, A., Jury, N., Martinez, P., Díaz, I., Amaro, A., Tran, H., Morales, D., Pertusa, M., et al.. (2022). Excessive release of inorganic polyphosphate by ALS/FTD astrocytes causes non-cell-autonomous toxicity to motoneurons. Neuron 110: 1656–1670.e12, https://doi.org/10.1016/j.neuron.2022.02.010. 3. Ayers, J.I., Xu, G., Dillon, K., Lu, Q., Chen, Z., Beckman, J., Moreno-Romero, A.K., Zamora, D.L., Galaleldeen, A., and Borchelt, D.R. (2021). Variation in the vulnerability of mice expressing human superoxide dismutase 1 to prion-like seeding: a study of the influence of primary amino acid sequence. Acta. Neuropathol. Commun. 9: 92, https://doi.org/10.1186/s40478-021-01191-w. 4. Bald, E.M., Nance, C.S., and Schultz, J.L. (2021). Melatonin may slow disease progression in amyotrophic lateral sclerosis: findings from the pooled resource open-access ALS clinic trials database. Muscle Nerve 63: 572–576, https://doi.org/10.1002/mus.27168. 5. Bär, P.R. (2000). Motor neuron disease in vitro: the use of cultured motor neurons to study amyotrophic lateral sclerosis. Eur. J. Pharmacol. 405: 285–295, https://doi.org/10.1016/s0014-2999(00)00560-4.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|